Desafíos de los países con economías de bajo-a-mediano ingreso para el manejo del cáncer de próstata por la pandemia por COVID-19: La perspectiva del Oncólogo Radioterápico
DOI:
https://doi.org/10.48193/revistamexicanadeurologa.v80i4.663Palabras clave:
Países en desarrollo, radioterapia, neoplasma prostático, COVID-19Resumen
Descripción: El COVID-19 representa un desafío para la práctica de la urología oncológica y radioterapia. Departamentos y grupos de colaboración internacional de radio oncología están compartiendo sus adaptaciones de práctica en respuesta a la pandemia. Esta revisión narrativa resume las recomendaciones actuales.
Relevancia: Existe la necesidad de definir qué pacientes son candidatos para un retraso seguro en el tratamiento hasta que la pandemia termine o se controle, de forma que se minimice la exposición del personal de salud y de los pacientes.
Conclusiones: Se recomienda la telemedicina para visitas de seguimiento. La vigilancia activa es el tratamiento preferido para el riesgo intermedio favorable. En enfermedad de mayor riesgo, la hormonoterapia retrasa la radioterapia de forma segura hasta 7 meses. La radiocirugía se sugiere en centros con tecnología y experiencia previa. Se recomienda un régimen de hipofraccionamiento moderado si no se dispone de radiocirugía / ultra hipofraccionamiento. El hipofraccionamiento debe implementarse si las capacidades de IGRT ya están en su lugar. Los países de bajos y medianos ingresos enfrentan desafíos para adaptar las recomendaciones para el manejo del cáncer de próstata durante la pandemia. El aplazamiento del tratamiento puede exceder la capacidad de los centros de oncología radioterápica después de la pandemia.
Referencias
Organization WH. Coronavirus disease 2019 (COVID-19): situation report, 29. World Health Organization; 2020 Feb.
Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. The Lancet Oncology. 2020;21(3):335–7. doi: 10.1016/S1470-2045(20)30096-6
Ueda M, Martins R, Hendrie PC, McDonnell T, Crews JR, Wong TL, et al. Managing Cancer Care During the COVID-19 Pandemic: Agility and Collaboration Toward a Common Goal. J Natl Compr Canc Netw. 2020;1–4. doi: 10.6004/jnccn.2020.7560
Yom S, Zietman A. Radiation Therapy in a Time of Disaster Int J Radiat Oncol Biol Phys. 2018; 100:832–3. doi: 10.1016/j.ijrobp.2017.12.001
Sandler H. Role of Overall Treatment Time in the Management of Prostate Cancer Patients: How to Manage Unscheduled Treatment Interruptions. Int J Radiat Oncol Biol Phys. 2018;100(4):841–2. doi: 10.1016/j.ijrobp.2017.12.278
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2018;68(6):394–424. doi: 10.3322/caac.21492
World Health Organization. Global Cancer Observatory. International Agency for Research on Cancer. Available from: https://gco.iarc.fr/
Taitt HE. Global Trends and Prostate Cancer: A Review of Incidence, Detection, and Mortality as Influenced by Race, Ethnicity, and Geographic Location: American Journal of Men’s Health. 2018;12(6):1807–1823. doi: 10.1177/1557988318798279
The European Society for Radiotherapy and Oncology. Radiotherapy in a time of crisis", ESTRO Presidents’ statement. ESTRO.
Oncology TL. COVID-19: global consequences for oncology. The Lancet Oncology. 2020;21(4):467. doi: 10.1016/S1470-2045(20)30175-3
Simcock R, Thomas TV, Estes C, Filippi AR, Katz MS, Pereira IJ, et al. COVID-19: Global radiation oncology’s targeted response for pandemic preparedness. ctRO. 2020 May 1;22:55–68. doi: 10.1016/j.ctro.2020.03.009
Zaorsky NG, Yu JB, McBride SM, Dess RT, Jackson WC, Mahal BA, et al. Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19. Advances in Radiation Oncology. 2020;0(0).
Gomez-Iturriaga A, Conde A, Henríquez I, Gómez-Caamaño A, San-Segundo G, Torrecilla JL, et al. Abordaje del cáncer de próstata en los servicios de Oncología Radioterápica: recomendaciones URONCOR durante la pandemia y periodo de recuperación posterior. Sociedad Española de Oncología Radioterápica (SEOR); p. 13.
Combs SE, Belka C, Niyazi M, Corradini S, Pigorsch S, Wilkens J, et al. First statement on preparation for the COVID-19 pandemic in large German Speaking University-based radiation oncology departments. Radiation Oncology. 2020;15(1):74. doi: 10.1186/s13014-020-01527-1
Filippi AR, Russi E, Magrini SM, Corvò R. Letter from Italy: First practical indications for radiation therapy departments during COVID-19 outbreak. International Journal of Radiation Oncology, Biology, Physics. 2020;107(3):597–9. doi: 10.1016/j.ijrobp.2020.03.007
Achard V, Tsoutsou P, Zilli T. Letter from Switzerland. International Journal of Radiation Oncology, Biology, Physics. 2020;107(3):600–1. doi: 10.1016/j.ijrobp.2020.03.008
Portaluri M, Tramacere F, Portaluri T, Gianicolo EAL. Southern Italy: How the Availability of Radiation Therapy, Patient Outcomes, and Risk to Health Care Providers Have Changed During the Coronavirus Disease 2019 Pandemic. Advances in Radiation Oncology. 2020;0(0). doi: 10.1016/j.adro.2020.03.016
Mohler JL, Horwitz E, Richey S. Guidelines Index Table of Contents Discussion. European Association of Urology; 2019 p. 165.
Neal DE, Metcalfe C, Donovan JL, Lane JA, Davis M, Young GJ, et al. Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received. European Urology. 2020;77(3):320–30. doi: 10.1016/j.eururo.2019.10.030
Zapatero A, Guerrero A, Maldonado X, Alvarez A, Segundo CGS, Rodríguez MAC, et al. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial. The Lancet Oncology. 2015;16(3):320–7. doi: 10.1016/S1470-2045(15)70045-8
Bolla M, Maingon P, Carrie C, Villa S, Kitsios P, Poortmans PMP, et al. Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991. JCO. 2016;34(15):1748–56. doi: 10.1200/JCO.2015.64.8055
Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. The Lancet Oncology. 2016;17(8):1047–60. doi: 10.1016/S1470-2045(16)30102-4
Widmark A, Gunnlaugsson A, Beckman L, Thellenberg-Karlsson C, Hoyer M, Lagerlund M, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. The Lancet. 2019;394(10196):385–95. doi: 10.1016/S0140-6736(19)31131-6
Abdollah F, Dalela D, Sood A, Keeley J, Alanee S, Briganti A, et al. Impact of Adjuvant Radiotherapy in Node-positive Prostate Cancer Patients: The Importance of Patient Selection. European Urology. 2018;74(3):253–6. doi: 10.1016/j.eururo.2018.04.017
Lieng H, Kneebone A, Hayden AJ, Christie DRH, Davis BJ, Eade TN, et al. Radiotherapy for node-positive prostate cancer: 2019 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group. Radiotherapy and Oncology. 2019; 140:68–75. doi: 10.1016/j.radonc.2019.05.016
Chin S, Fatimilehin A, Walshaw R, Argarwal A, Mistry H, Elliott T, et al. Ten-Year Outcomes of Moderately Hypofractionated Salvage Postprostatectomy Radiation Therapy and External Validation of a Contemporary Multivariable Nomogram for Biochemical Failure. International Journal of Radiation Oncology, Biology, Physics. 2020;107(2):288–96. doi: 10.1016/j.ijrobp.2020.01.008
Segundo CG-S, Couñago F, Gomez-Iturriaga A. Androgen Deprivation Therapy and Salvage Radiotherapy: Are We Missing Something? European Urology. 2019;76(2):260–1. doi: 10.1016/j.eururo.2019.01.045
Ghadjar P, Aebersold DM, Albrecht C, Böhmer D, Flentje M, Ganswindt U, et al. Use of androgen deprivation and salvage radiation therapy for patients with prostate cancer and biochemical recurrence after prostatectomy. Strahlenther Onkol. 2018;194(7):619–26. doi: 10.1007/s00066-018-1269-3
Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. The Lancet. 2018;392(10162):2353–66. doi: 10.1016/S0140-6736(18)32486-3
Zelefsky MJ, Kuban DA, Levy LB, Potters L, Beyer DC, Blasko JC, et al. Multi-institutional analysis of long-term outcome for stages T1–T2 prostate cancer treated with permanent seed implantation. International Journal of Radiation Oncology, Biology, Physics. 2007;67(2):327–33. doi: 10.1016/j.ijrobp.2006.08.056
Frankland J, Brodie H, Cooke D, Foster C, Foster R, Gage H, et al. Follow-up care after treatment for prostate cancer: evaluation of a supported self-management and remote surveillance programme. BMC Cancer. 2019;19(1):368. doi: 10.1186/s12885-019-5561-0
Ohannessian R, Duong TA, Odone A. Global Telemedicine Implementation and Integration Within Health Systems to Fight the COVID-19 Pandemic: A Call to Action. JMIR Public Health and Surveillance. 2020;6(2):e18810. doi: 10.2196/18810
Holeman I, Evans J, Kane D, Grant L, Pagliari C, Weller D. Mobile health for cancer in low to middle income countries: priorities for research and development. Eur J Cancer Care. 2014;23(6):750–6. doi: 10.1111/ecc.12250
Bhatt S, Evans J, Gupta S. Barriers to Scale of Digital Health Systems for Cancer Care and Control in Last-Mile Settings. Journal of Global Oncology. 2017;4: JGO.2016.007179. doi: 10.1200/JGO.2016.007179
Braunstein LZ, Gillespie EF, Hong L, Xu A, Bakhoum SF, Cuaron J, et al. Breast Radiation Therapy Under COVID-19 Pandemic Resource Constraints—Approaches to Defer or Shorten Treatment from a Comprehensive Cancer Center in the United States. Advances in Radiation Oncology. 2020;0(0). doi: 10.1016/j.adro.2020.03.013
Allemani C, Matsuda T, Carlo VD, Harewood R, Matz M, Nikšić M, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. The Lancet. 2018;391(10125):1023–75. doi: 10.1016/S0140-6736(17)33326-3
Pisansky TM, Suman VJ, Roach M, Sandler HM. Reporting of results in DART01/05 GICOR. The Lancet Oncology. 2015;16(6):e258. doi: 10.1016/S1470-2045(15)70243-3
Carneiro A, Wroclawski ML, Nahar B, Soares A, Cardoso AP, Kim NJ, et al. Impact of the COVID-19 Pandemic on the Urologist’s clinical practice in Brazil: a management guideline proposal for low- and middle-income countries during the crisis period. Int Braz J Urol. 2020;501–10.
Crawford ED, Sartor O, Chu F, Perez R, Karlin G, Garrett JS. A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol. 2006;175(2):533–6. doi: 10.1016/S0022-5347(05)00161-8
Morgan SC, Hoffman K, Loblaw DA, Buyyounouski MK, Patton C, Barocas D, et al. Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO, and AUA Evidence-Based Guideline. Practical Radiation Oncology. 2018;8(6):354–60. doi: 10.1016/j.prro.2018.08.002
Höcht S, Aebersold DM, Albrecht C, Böhmer D, Flentje M, Ganswindt U, et al. Hypofractionated radiotherapy for localized prostate cancer. Strahlenther Onkol. 2017;193(1):1–12. doi: 10.1007/s00066-016-1041-5
Rosenblatt E, Zubizarreta E. Radiotherapy in Cancer Care: Facing the Global Challenge. Vienna: International Atomic Energy Agency; 2017. 578 p.
American Urological Association. Prostate Cancer: Hypofractionated Radiotherapy Guideline An ASTRO, ASCO, and AUA Evidence-Based Guideline. American Urological Association. 2018.
Rosenblatt E, Acuña O, Abdel-Wahab M. The Challenge of Global Radiation Therapy: An IAEA Perspective. International Journal of Radiation Oncology, Biology, Physics. 2015;91(4):687–9. doi: 10.1016/j.ijrobp.2014.12.008
Burki TK. Cancer guidelines during the COVID-19 pandemic. The Lancet Oncology. 2020;21(5):629–30. doi: 10.1016/S1470-2045(20)30217-5
Atun R, Jaffray DA, Barton MB, Bray F, Baumann M, Vikram B, et al. Expanding global access to radiotherapy. The Lancet Oncology. 2015;16(10):1153–86. doi: 10.1016/S1470-2045(15)00222-3
